乳腺癌分子靶向治疗现状

Present Status of Molecular Targeted Therapy for Breast Cancer

近年来,乳腺癌的分子靶向治疗取得了长足的发展。曲妥珠单抗联合化疗已成为Her-2阳性乳腺癌患者的标准一线治疗。全文从抗Her-2治疗药物,PI3K/AKT/m TOR通路中的抑制剂,抗血管生成治疗药物,针对BRCA1/2突变的PARP抑制剂,细胞周期蛋白依赖性激酶4和6(CDK4/6)抑制剂几个方面就当前乳腺癌分子靶向治疗现状作一综述。

In recent years,the molecular targeted therapy for breast cancer has gained substantial development. Trastuzumab combined with chemotherapy has become the first-line therapy for Her-2 positive breast cancer patients. In this review,agents that target Her-2,inhibitors of PI3K/AKT/m TOR pathway,antiangiogenesis drugs,PARP inhibitors in BRCA1/2 mutation-associated patients and inhibitors of cyclin-dependent kinase4/6 are introduced.